Global Type 2 Diabetes Market is segmented By Drug Class (Oral Antidiabetics, Insulin), By Distribution Channel (Hospitals, Retail Pharmacy, Online Pharmacy), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029
Market Overview
The Global Type 2 Diabetes Market is expected to grow at a CAGR of 7.5% during the forecasting period (2022-2029).
-
Diabetes is a chronic condition characterized by high blood sugar, insulin resistance, and a relative lack of insulin.
-
Type 2 diabetes (T2D) is the most prevalent form of diabetes mellitus. Type 2 diabetes is treated with lifestyle modifications, oral medications, and insulin.
-
Around 90% of people with diabetes have type 2 diabetes.
-
WHO predicts that T2D will be the seventh leading cause of death by 2030.
-
The global Type 2 diabetes market is estimated to reach USD 64 billion by 2026.
Market Growth
-
An ever-increasing prevalence of diabetes and increased usage of anti-diabetic drugs with non-glycemic benefits will drive the market.
-
Also, the rich pipeline of novel agents is expected to get launched.
-
However, the availability of inexpensive generics will hamper the market growth.
Market Segmentation
-
Global Type 2 diabetes market report segments the market by drug class, distribution channel, and by region.
-
Based on part treatment type, the market is segmented into Biguanides, Sulfonylureas, Alpha-glucosidase inhibitors, Thiazolidinediones, Glucagon-like peptide-1 receptor agonists, Dipeptidyl peptidase four inhibitors, Sodium-glucose cotransporter two inhibitors, and Insulin.
-
Geographically, the market is segmented into five major regions, namely North America, South America, Europe, Asia Pacific, and RoW.
-
North America is the largest market for Type 2 diabetes owing to the high market penetration of insulin and other antidiabetic drugs.
-
The region was the most mature market in 2017 accounting for over 45% of the market.
Scope of the Report
-
The report also profiles the following companies of type 2 diabetes market – Novo Nordisk, Merck & Co. Inc., Pfizer, Astra Zeneca, Bristol-Myers Squibb, Eli Lilly, Takeda, Johnson & Johnson, Sanofi, and others.
By Drug Class
-
Biguanides
-
Sulfonylureas
-
Alpha-glucosidase inhibitors
-
Thiazolidinediones
-
Glucagon-like peptide-1 receptor agonists (GLP-1 agonists)
-
Dipeptidyl peptidase four inhibitors (DPP-4 inhibitors)
-
Sodium-glucose cotransporter two inhibitors (SGLT – 2)
-
Insulin
By Distribution Channel
-
Hospitals
-
Retail Pharmacy
-
Online Pharmacy
By Region
-
Asia Pacific (China, Japan, India, Australia, Rest of Asia Pacific)
-
Europe (Germany, France, The UK, Italy, Spain, Rest of Europe)
-
North America (The USA, Canada, Mexico)
-
South America (Brazil, Argentina, Rest of South America)
-
Rest of the World